Evolving synergistic combinations of targeted immunotherapies to combat cancer - PubMed (original) (raw)

Review

doi: 10.1038/nrc3973.

Affiliations

• PMID: 26205340
• DOI: 10.1038/nrc3973

Review

Evolving synergistic combinations of targeted immunotherapies to combat cancer

Ignacio Melero et al. Nat Rev Cancer. 2015 Aug.

Abstract

Immunotherapy has now been clinically validated as an effective treatment for many cancers. There is tremendous potential for synergistic combinations of immunotherapy agents and for combining immunotherapy agents with conventional cancer treatments. Clinical trials combining blockade of cytotoxic T lymphocyte-associated antigen 4 (CTLA4) and programmed cell death protein 1 (PD1) may serve as a paradigm to guide future approaches to immuno-oncology combination therapy. In this Review, we discuss progress in the synergistic design of immune-targeting combination therapies and highlight the challenges involved in tailoring such strategies to provide maximal benefit to patients.

PubMed Disclaimer

Similar articles

• Preclinical Rationale and Clinical Considerations for Radiotherapy Plus Immunotherapy: Going Beyond Local Control.
  Schoenhals JE, Seyedin SN, Tang C, Cortez MA, Niknam S, Tsouko E, Chang JY, Hahn SM, Welsh JW. Schoenhals JE, et al. Cancer J. 2016 Mar-Apr;22(2):130-7. doi: 10.1097/PPO.0000000000000181. Cancer J. 2016. PMID: 27111909 Review.
• Combination cancer immunotherapy and new immunomodulatory targets.
  Mahoney KM, Rennert PD, Freeman GJ. Mahoney KM, et al. Nat Rev Drug Discov. 2015 Aug;14(8):561-84. doi: 10.1038/nrd4591. Nat Rev Drug Discov. 2015. PMID: 26228759 Review.
• Emerging Opportunities and Challenges in Cancer Immunotherapy.
  Whiteside TL, Demaria S, Rodriguez-Ruiz ME, Zarour HM, Melero I. Whiteside TL, et al. Clin Cancer Res. 2016 Apr 15;22(8):1845-55. doi: 10.1158/1078-0432.CCR-16-0049. Clin Cancer Res. 2016. PMID: 27084738 Free PMC article. Review.
• Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
  Jia H, Truica CI, Wang B, Wang Y, Ren X, Harvey HA, Song J, Yang JM. Jia H, et al. Drug Resist Updat. 2017 May;32:1-15. doi: 10.1016/j.drup.2017.07.002. Epub 2017 Aug 19. Drug Resist Updat. 2017. PMID: 29145974 Review.
• Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy.
  Rojas JJ, Sampath P, Hou W, Thorne SH. Rojas JJ, et al. Clin Cancer Res. 2015 Dec 15;21(24):5543-51. doi: 10.1158/1078-0432.CCR-14-2009. Epub 2015 Jul 17. Clin Cancer Res. 2015. PMID: 26187615 Free PMC article.

Cited by

• Tumor Microenvironment Multiple Responsive Nanoparticles for Targeted Delivery of Doxorubicin and CpG Against Triple-Negative Breast Cancer.
  Gu F, Hu C, Cao W, Li C, Xia Q, Gao Y, Liu Y, Gao S. Gu F, et al. Int J Nanomedicine. 2022 Sep 20;17:4401-4417. doi: 10.2147/IJN.S377702. eCollection 2022. Int J Nanomedicine. 2022. PMID: 36164553 Free PMC article.
• A Perspective of Immunotherapy for Prostate Cancer.
  Silvestri I, Cattarino S, Giantulli S, Nazzari C, Collalti G, Sciarra A. Silvestri I, et al. Cancers (Basel). 2016 Jul 7;8(7):64. doi: 10.3390/cancers8070064. Cancers (Basel). 2016. PMID: 27399780 Free PMC article. Review.
• Type I Interferons and Cancer: An Evolving Story Demanding Novel Clinical Applications.
  Aricò E, Castiello L, Capone I, Gabriele L, Belardelli F. Aricò E, et al. Cancers (Basel). 2019 Dec 4;11(12):1943. doi: 10.3390/cancers11121943. Cancers (Basel). 2019. PMID: 31817234 Free PMC article.
• Supramolecular Biomaterials for Cancer Immunotherapy.
  Liang H, Lu Q, Yang J, Yu G. Liang H, et al. Research (Wash D C). 2023 Sep 12;6:0211. doi: 10.34133/research.0211. eCollection 2023. Research (Wash D C). 2023. PMID: 37705962 Free PMC article. Review.
• Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen.
  Wculek SK, Amores-Iniesta J, Conde-Garrosa R, Khouili SC, Melero I, Sancho D. Wculek SK, et al. J Immunother Cancer. 2019 Apr 8;7(1):100. doi: 10.1186/s40425-019-0565-5. J Immunother Cancer. 2019. PMID: 30961656 Free PMC article.

References

1. 1. Clin Cancer Res. 2011 Jun 15;17(12):4101-9 - PubMed
2. 1. J Immunol. 2006 Sep 1;177(5):2969-75 - PubMed
3. 1. Oncoimmunology. 2014 May 14;3:e28780 - PubMed
4. 1. Nature. 2006 Feb 9;439(7077):682-7 - PubMed
5. 1. Arch Immunol Ther Exp (Warsz). 2002;50(1):13-8 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Nature Publishing Group

• Other Literature Sources

  • The Lens - Patent Citations Database

• Molecular Biology Databases

  • Guide to Pharmacology

• Research Materials

  • NCI CPTC Antibody Characterization Program